Thornton Michael Milos 4
4 · ENDRA Life Sciences Inc. · Filed Dec 11, 2019
Insider Transaction Report
Form 4
Thornton Michael Milos
Chief Technology Officer
Transactions
- Award
Warrants
2019-12-11+50,252→ 50,252 totalExercise: $0.87From: 2019-12-11Exp: 2024-12-11→ Common Stock (50,252 underlying) - Award
Series A Convertible Preferred Stock
2019-12-11$1143.68/sh+43.719$50,001→ 43.719 totalExercise: $0.87From: 2019-12-11→ Common Stock (50,252 underlying) - Award
Stock option (right to buy)
2019-12-11+575,906→ 575,906 totalExercise: $0.90Exp: 2029-12-11→ Common Stock (575,906 underlying)
Footnotes (4)
- [F1]These options vest and become exercisable in three equal annual installments beginning on the one year anniversary of the grant date.
- [F2]The Series A preferred stock has a face value of $1,000 per share and accrues dividends thereon at an annual rate of 6.0%. The face value plus accrued and unpaid dividends of the Series A preferred stock is convertible into common stock at a price per share of $0.87.
- [F3]The Series A preferred stock has no expiration date.
- [F4]The Warrants were issued for no additional consideration in connection with the purchase of the Series A preferred stock.